|
|
| Id: | 26940
| | Autor: | Gomes, Maria Katia; Stefani, Mariane; Sousa, AnaLúcia O. M; Rabello, Paula F. B; Pennini, Silmara; Narahashi, Kazuê; Ueda, Emília; Daxbacher, Egon R; Aslanian, Flávia M. N. P; Nery, José A. C; Sales, Anna Maria; Oliveira, Maria Leide W; Martelli, Celina Maria Turchi. | | Título: | Single lesion leprosy pacients multicentric cohort treated with single dose drug therapy: findings on three-year follow-up and public health perspective in Brazil.
| | Fonte: | In: Universidade Federal do Rio de Janeiro.Instituto de Estudos em Saúde Coletiva.Investigações em sistema de saúde e controle da hanseníase^ipt. Rio de Janeiro, s.n, abr.-jun., 2008. p.363-376.
| | Resumo: | Single skin lesion, paucibacillary (SSL-PB) leprosy is considered and early disease manifesation. This study the clinical outcome of a cohort of 259 newly diagnosed SSL-PB treated with one dose of rifampicin, ofloxacin, minocycline (ROM) and followed-up for three-years. Patients were recruited from the North, Central West and Southeast regions in Brazil (1997-2001). The result expected with ROM therapy was disappearance or the reduction of lesion size. Manifestation that required additional intervention were considered as poor clinical outcome: type-1 reaction (T1R) with or without neuritis alone, increase in lesion size and shift from paucibacillary to multibacillary. The incidence of poor clinical outcome was calculated by person-month and with the Kaplan-Meier methods. 61.8% of the participants were females, mean age 32.2, and 67,2% had borderline tuberculoid (BT) or tuberculoid forms. T1R was the predominant event; shift from paucibacillary to multibacillaru was rare. 92.0% of the volunteers shown no events during the first year, the same occurring to 80.6% of them after 3 years of clinical monitoring. The probability of remaining event-free was highest among those 40 years old or younger. Poor outcome predominated among BT patients. Extended monitoring of SSL-PB leprosy cases under minimal therapy provided valuable case management information for reference centers. (AU)^ien.
| | Descritores: | Hanseníase/epidemiol
Hanseníase/imunol
Hanseníase/fisiopatol
Dose Única/métodos
Saúde Pública/métodos
| | Localização: | BR191.1; 01224/D.A |
|
